ValueAct reports 20.3% ownership interest in Valeant Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., June 17 - Investors led by ValueAct Master Fund, LP bought 876,476 shares of Valeant Pharmaceuticals International between June 2 and June 16 priced from $22.53 to $23.61 each, according to a schedule 13D/A filed on Wednesday with the Securities and Exchange Commission.

On May 15, ValueAct bought 56,264 shares of the company's stock, a prior SEC filing said.

The investors beneficially own 16,709,669 shares, or 20.3%, the Costa Mesa, Calif., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.